|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Herbst RS, Heymach JV and Lippman SM: Lung
cancer. N Engl J Med. 359:1367–1380. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Daryadel A, Grifone RF, Simon HU and
Yousefi S: Apoptotic neutrophils release macrophage migration
inhibitory factor upon stimulation with tumor necrosis
factor-alpha. J Biol Chem. 281:27653–27661. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shimizu T: Role of macrophage migration
inhibitory factor (MIF) in the skin. J Dermatol Sci. 37:65–73.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Verschuren L, Lindeman JH, van Bockel JH,
Abdul-Hussien H, Kooistra T and Kleemann R: Upregulation and
coexpression of MIF and matrix metalloproteinases in human
abdominal aortic aneurysms. Antioxid Redox Signal. 7:1195–1202.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Morand EF, Leech M and Bernhagen J: MIF: A
new cytokine link between rheumatoid arthritis and atherosclerosis.
Nat Rev Drug Discov. 5:399–410. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen D, Xia M, Hayford C, Tham L, Semik V,
Hurst S, Chen Y, Tam HH, Pan J, Wang Y, et al: Expression of human
tissue factor pathway inhibitor on vascular smooth muscle cells
inhibits secretion of macrophage migration inhibitory factor and
attenuates atherosclerosis in ApoE−/− mice. Circulation.
131:1350–1360. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Assis DN, Leng L, Du X, Zhang CK, Grieb G,
Merk M, Garcia AB, McCrann C, Chapiro J, Meinhardt A, et al: The
role of macrophage migration inhibitory factor in autoimmune liver
disease. Hepatology. 59:580–591. 2014. View Article : Google Scholar
|
|
9
|
Gordon-Weeks AN, Lim SY, Yuzhalin AE,
Jones K and Muschel R: Macrophage migration inhibitory factor: A
key cytokine and therapeutic target in colon cancer. Cytokine
Growth Factor Rev. 26:451–461. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tas F, Karabulut S, Serilmez M, Ciftci R
and Duranyildiz D: Serum levels of macrophage migration-inhibitory
factor (MIF) have diagnostic, predictive and prognostic roles in
epithelial ovarian cancer patients. Tumour Biol. 35:3327–3331.
2014. View Article : Google Scholar
|
|
11
|
Meyer-Siegler KL, Vera PL, Iczkowski KA,
Bifulco C, Lee A, Gregersen PK, Leng L and Bucala R: Macrophage
migration inhibitory factor (MIF) gene polymorphisms are associated
with increased prostate cancer incidence. Genes Immun. 8:646–652.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lv W, Chen N, Lin Y, Ma H, Ruan Y, Li Z,
Li X, Pan X and Tian X: Macrophage migration inhibitory factor
promotes breast cancer metastasis via activation of HMGB1/TLR4/NF
kappa B axis. Cancer Lett. 375:245–255. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhao YM, Wang L, Dai Z, Wang DD, Hei ZY,
Zhang N, Fu XT, Wang XL, Zhang SC, Qin LX, et al: Validity of
plasma macrophage migration inhibitory factor for diagnosis and
prognosis of hepatocellular carcinoma. Int J Cancer. 129:2463–2472.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Morris KT, Nofchissey RA, Pinchuk IV and
Beswick EJ: Chronic macrophage migration inhibitory factor exposure
induces mesenchymal epithelial transition and promotes gastric and
colon cancers. PLoS One. 9:e986562014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cates JM, Friedman DB, Seeley EH, Dupont
WD, Schwartz HS, Holt GE, Caprioli RM and Young PP: Proteomic
analysis of osteogenic sarcoma: Association of tumour necrosis
factor with poor prognosis. Int J Exp Pathol. 91:335–349. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xu L, Li Y, Sun H, Zhen X, Qiao C, Tian S
and Hou T: Current developments of macrophage migration inhibitory
factor (MIF) inhibitors. Drug Discov Today. 18:592–600. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kyriakis JM: Thinking outside the box
about Ras. J Biol Chem. 284:10993–10994. 2009. View Article : Google Scholar :
|
|
18
|
Welford SM, Bedogni B, Gradin K,
Poellinger L, Broome Powell M and Giaccia AJ: HIF1alpha delays
premature senescence through the activation of MIF. Genes Dev.
20:3366–3371. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fingerle-Rowson G, Petrenko O, Metz CN,
Forsthuber TG, Mitchell R, Huss R, Moll U, Müller W and Bucala R:
The p53-dependent effects of macrophage migration inhibitory factor
revealed by gene targeting. Proc Natl Acad Sci USA. 100:9354–9359.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Martin J, Duncan FJ, Keiser T, Shin S,
Kusewitt DF, Oberyszyn T, Satoskar AR and VanBuskirk AM: Macrophage
migration inhibitory factor (MIF) plays a critical role in
pathogenesis of ultraviolet-B (UVB)-induced nonmelanoma skin cancer
(NMSC). FASEB J. 23:720–730. 2009. View Article : Google Scholar
|
|
21
|
Winner M, Koong AC, Rendon BE, Zundel W
and Mitchell RA: Amplification of tumor hypoxic responses by
macrophage migration inhibitory factor-dependent hypoxia-inducible
factor stabilization. Cancer Res. 67:186–193. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
White ES, Strom SR, Wys NL and Arenberg
DA: Non-small cell lung cancer cells induce monocytes to increase
expression of angiogenic activity. J Immunol. 166:7549–7555. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
White ES, Flaherty KR, Carskadon S, Brant
A, Iannettoni MD, Yee J, Orringer MB and Arenberg DA: Macrophage
migration inhibitory factor and CXC chemokine expression in
non-small cell lung cancer: Role in angiogenesis and prognosis.
Clin Cancer Res. 9:853–860. 2003.PubMed/NCBI
|
|
24
|
Arenberg D, Luckhardt TR, Carskadon S,
Zhao L, Amin MA and Koch AE: Macrophage migration inhibitory factor
promotes tumor growth in the context of lung injury and repair. Am
J Respir Crit Care Med. 182:1030–1037. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mawhinney L, Armstrong ME, O' Reilly C,
Bucala R, Leng L, Fingerle-Rowson G, Fayne D, Keane MP, Tynan A,
Maher L, et al: Macrophage migration inhibitory factor (MIF)
enzymatic activity and lung cancer. Mol Med. 20:729–735.
2015.PubMed/NCBI
|
|
26
|
Rendon BE, Roger T, Teneng I, Zhao M,
Al-Abed Y, Calandra T and Mitchell RA: Regulation of human lung
adenocarcinoma cell migration and invasion by macrophage migration
inhibitory factor. J Biol Chem. 282:29910–29918. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu J, Zhang C, Wu R, Lin M, Liang Y, Liu
J, Wang X, Yang B and Feng Z: RRAD inhibits the Warburg effect
through negative regulation of the NF-κB signaling. Oncotarget.
6:14982–14992. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Iansante V, Choy PM, Fung SW, Liu Y, Chai
JG, Dyson J, Del Rio A, D'Santos C, Williams R, Chokshi S, et al:
PARP14 promotes the Warburg effect in hepatocellular carcinoma by
inhibiting JNK1-dependent PKM2 phosphorylation and activation. Nat
Commun. 6:78822015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Benigni F, Atsumi T, Calandra T, Metz C,
Echtenacher B, Peng T and Bucala R: The proinflammatory mediator
macrophage migration inhibitory factor induces glucose catabolism
in muscle. J Clin Invest. 106:1291–1300. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Waeber G, Calandra T, Roduit R, Haefliger
JA, Bonny C, Thompson N, Thorens B, Temler E, Meinhardt A, Bacher
M, et al: Insulin secretion is regulated by the glucose-dependent
production of islet beta cell macrophage migration inhibitory
factor. Proc Natl Acad Sci USA. 94:4782–4787. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lv XB, Liu L, Cheng C, Yu B, Xiong L, Hu
K, Tang J, Zeng L and Sang Y: SUN2 exerts tumor suppressor
functions by suppressing the Warburg effect in lung cancer. Sci
Rep. 5:179402015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cairns RA: Drivers of the Warburg
phenotype. Cancer J. 21:56–61. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jia YY, Zhao JY, Li BL, Gao K, Song Y, Liu
MY, Yang XJ, Xue Y, Wen AD and Shi L: miR-592/WSB1/HIF-1α axis
inhibits glycolytic metabolism to decrease hepatocellular carcinoma
growth. Oncotarget. 7:35257–35269. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Johnson RF and Perkins ND: Nuclear
factor-κB, p53, and mitochondria: Regulation of cellular metabolism
and the Warburg effect. Trends Biochem Sci. 37:317–324. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kamimura A, Kamachi M, Nishihira J, Ogura
S, Isobe H, Dosaka-Akita H, Ogata A, Shindoh M, Ohbuchi T and
Kawakami Y: Intracellular distribution of macrophage migration
inhibitory factor predicts the prognosis of patients with
adenocarcinoma of the lung. Cancer. 89:334–341. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gámez-Pozo A, Sánchez-Navarro I, Calvo E,
Agulló-Ortuño MT, López-Vacas R, Díaz E, Camafeita E, Nistal M,
Madero R, Espinosa E, et al: PTRF/cavin-1 and MIF proteins are
identified as non-small cell lung cancer biomarkers by label-free
proteomics. PLoS One. 7:e337522012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Guo Y, Hou J, Luo Y and Wang D: Functional
disruption of macrophage migration inhibitory factor (MIF)
suppresses proliferation of human H460 lung cancer cells by
caspase-dependent apoptosis. Cancer Cell Int. 13:282013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Vousden KH and Ryan KM: p53 and
metabolism. Nat Rev Cancer. 9:691–700. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Brock SE, Rendon BE, Yaddanapudi K and
Mitchell RA: Negative regulation of AMP-activated protein kinase
(AMPK) activity by macrophage migration inhibitory factor (MIF)
family members in non-small cell lung carcinomas. J Biol Chem.
287:37917–37925. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Courtnay R, Ngo DC, Malik N, Ververis K,
Tortorella SM and Karagiannis TC: Cancer metabolism and the Warburg
effect: The role of HIF-1 and PI3K. Mol Biol Rep. 42:841–851. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kaelin WG Jr: Cancer and altered
metabolism: Potential importance of hypoxia-inducible factor and
2-oxoglutarate-dependent dioxygenases. Cold Spring Harb Symp Quant
Biol. 76:335–345. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yao G, Zhang Q, Doeppner TR, Niu F, Li Q,
Yang Y, Kuckelkorn U, Hagemann N, Li W, Hermann DM, et al: LDL
suppresses angiogenesis through disruption of the HIF pathway via
NF-κB inhibition which is reversed by the proteasome inhibitor
BSc2118. Oncotarget. 6:30251–30262. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Shin DH, Li SH, Yang SW, Lee BL, Lee MK
and Park JW: Inhibitor of nuclear factor-kappaB alpha derepresses
hypoxia-inducible factor-1 during moderate hypoxia by sequestering
factor inhibiting hypoxia-inducible factor from hypoxia-inducible
factor 1alpha. FEBS J. 276:3470–3480. 2009. View Article : Google Scholar : PubMed/NCBI
|
